Predictors of responses to immune checkpoint blockade in advanced melanoma

N. Jacquelot; M. P. Roberti; D. P. Enot; S. Rusakiewicz; N. Ternès; S. Jegou; D. M. Woods; A. L. Sodré; M. Hansen; Y. Meirow; M. Sade-Feldman; A. Burra; S. S. Kwek; C. Flament; M. Messaoudene; C. P.M. Duong; L. Chen; B. S. Kwon; A. C. Anderson; V. K. Kuchroo; B. Weide; F. Aubin; C. Borg; S. Dalle; O. Beatrix; M. Ayyoub; B. Balme; G. Tomasic; A. M. Di Giacomo; M. Maio; D. Schadendorf; I. Melero; B. Dréno; A. Khammari; R. Dummer; M. Levesque; Y. Koguchi; L. Fong; M. Lotem; M. Baniyash; H. Schmidt; I. M. Svane; G. Kroemer; A. Marabelle; S. Michiels; A. Cavalcanti; M. J. Smyth; J. S. Weber; A. M. Eggermont; L. Zitvogel

doi:10.1038/s41467-017-00608-2

Predictors of responses to immune checkpoint blockade in advanced melanoma

N. Jacquelot, M. P. Roberti, D. P. Enot, S. Rusakiewicz, N. Ternès, S. Jegou, D. M. Woods, A. L. Sodré, M. Hansen, Y. Meirow, M. Sade-Feldman, A. Burra, S. S. Kwek, C. Flament, M. Messaoudene, C. P.M. Duong, L. Chen, B. S. Kwon, A. C. Anderson, V. K. KuchrooB. Weide, F. Aubin, C. Borg, S. Dalle, O. Beatrix, M. Ayyoub, B. Balme, G. Tomasic, A. M. Di Giacomo, M. Maio, D. Schadendorf, I. Melero, B. Dréno, A. Khammari, R. Dummer, M. Levesque, Y. Koguchi, L. Fong, M. Lotem, M. Baniyash, H. Schmidt, I. M. Svane, G. Kroemer, A. Marabelle, S. Michiels, A. Cavalcanti, M. J. Smyth, J. S. Weber, A. M. Eggermont, L. Zitvogel^*

^*Corresponding author for this work

Department of Immunology and Cancer Research

Research output: Contribution to journal › Article › peer-review

161 Scopus citations

Abstract

Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given the frequency of immune related adverse events and increasing use of ICB, predictors of response to CTLA-4 and/or PD-1 blockade represent unmet clinical needs. Using a systems biology-based approach to an assessment of 779 paired blood and tumor markers in 37 stage III MMel patients, we analyzed association between blood immune parameters and the functional immune reactivity of tumor-infiltrating cells after ex vivo exposure to ICB. Based on this assay, we retrospectively observed, in eight cohorts enrolling 190 MMel patients treated with ipilimumab, that PD-L1 expression on peripheral T cells was prognostic on overall and progression-free survival. Moreover, detectable CD137 on circulating CD8⁺ T cells was associated with the disease-free status of resected stage III MMel patients after adjuvant ipilimumab + nivolumab (but not nivolumab alone). These biomarkers should be validated in prospective trials in MMel.

Original language	English
Article number	592
Journal	Nature Communications
Volume	8
Issue number	1
DOIs	https://doi.org/10.1038/s41467-017-00608-2
State	Published - 1 Dec 2017

Bibliographical note

Funding Information:
Competing interests: L.C. receives consulting fees from Medimmune and Pfizer and patent/licensing payments from Bristol-Myers Squibb (BMS); L.C. currently receives sponsored research funding from Boehringer Ingelheim, Pfizer and Nextcure. L.F. received research funding from BMS, Merck, Medimmune, Abbvie and Genentech. S.D. is principal investigator, received research grants and congress invitation by BMS. B.W. reports research grants, speaker honoraria, and travel support from MSD/ Merck and BMS. I.M. has served as an advisor for Roche-Genentech, BMS, Boehringer Ingelheim, Novartis, Astra-Zeneca Medimmune and Incyte. AME participated on scientific advisory boards for Actelion, Agenus, Bayer, BMS, GlaxoSmithKline (GSK), HalioDx, Incyte, MSD, Nektar, Novartis, Pfizer, and Sanofi. L.Z. is on the Transgene administrative board and Lytix Pharma scientific advisory board and is the main founder of EverImmune. M.J.S. has research agreements with BMS and Corvus Pharmaceuticals and has received patent payments from BMS. A.M.D.G. has honoraria for certified continuing education, and travel supports from BMS, Astra-Zeneca, Roche and MSD. M. Maio has honoraria for certified continuing education, for consulting and advisory roles, research funding and travel supports from BMS, Roche and MSD. A.C.A. is a member of the SAB for Tizona Therapeutics, Potenza Therapeutics, and Idea Pharmaceuticals, which have interests in cancer immunology. A.K. received congress invitation from BMS. C.B. reports honoraria from Lilly, BMS and MSD, serves as advisory roles from Servier and Roche and receives research grants from Roche. B.D. reports BMS board participation, investigator for BMS clinical trials and congress invitation. Y.K. reports ownership interest in a patent regarding serum biomarkers for ipilimumab treatment (WO2016127052.A1). M.H. is a full time employee of Symphogen A/S Denmark. IMS reports honoraria for teaching, consultancy, and advisatory roles from BMS, Roche, Novartis, Genentech, and MSD, research agreement with BMS, Novartis, and Symphogen and co-founder of IO Biotech. R.D. receives research funding from Novartis, MSD, BMS, Roche, GSK and has a consultant or advisory board relationship with Novartis, MSD, BMS, Roche, GSK, Amgen, Takeda, Pierre Fabre. M.B., Y.M., and M.S.F. were supported by the NORFAR program, the Academic Research Office of the Chief Scientist, Ministry of Economy, Israel and collaborated with improdia.co.il. H.S. reports honoraria for teaching, consultancy and advisory boards from BMS, Roche, Merck and Novartis. J.S.W. receives travel grants from and participated to scientific advisory boards of BMS, Merck, Astra-Zeneca, Genentech and EMD Serono. A.M. received consulting honoraria from Roche/Genentech, BMS, Merck (MSD), Astra-Zeneca and participated to scientific advisory boards of Roche/Genentech, Pfizer/Merck serono, Novartis, GSK, eTherna, Kyowa Kirin, Symphogen, Genmab, Amgen, Lytix, Nektar, Seatlle Genetics, Transgene and Flexus Bio. The remaining authors declare no competing financial interests.

Funding Information:
The authors thank the patients and their families for their acceptance to participate in this study. This work was supported by Institut National du Cancer INCa, ANR, Ligue contre le cancer (équipe labellisée de L.Z.) and Swiss Bridge Foundation, ISREC Foundation, LABEX OncoImmunology, la direction générale de l’offre de soins (DGOS), Université Paris-Sud, SIRIC SOCRATE (INCa/DGOS/INSERM 6043), PACRI network and PIA2 TORINO-LUMIERE. N.J. received a fellowship from Cancéropole Idf. M.J.S. was supported by a National Health and Medical Research Council of Australia Senior Principal Research Fellowship.

Publisher Copyright:
© 2017 The Author(s).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41467-017-00608-2

Cite this

Jacquelot, N., Roberti, M. P., Enot, D. P., Rusakiewicz, S., Ternès, N., Jegou, S., Woods, D. M., Sodré, A. L., Hansen, M., Meirow, Y., Sade-Feldman, M., Burra, A., Kwek, S. S., Flament, C., Messaoudene, M., Duong, C. P. M., Chen, L., Kwon, B. S., Anderson, A. C., ... Zitvogel, L. (2017). Predictors of responses to immune checkpoint blockade in advanced melanoma. Nature Communications, 8(1), Article 592. https://doi.org/10.1038/s41467-017-00608-2

@article{fd774171c9794e5ab06a4ec78ad361f0,

title = "Predictors of responses to immune checkpoint blockade in advanced melanoma",

abstract = "Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given the frequency of immune related adverse events and increasing use of ICB, predictors of response to CTLA-4 and/or PD-1 blockade represent unmet clinical needs. Using a systems biology-based approach to an assessment of 779 paired blood and tumor markers in 37 stage III MMel patients, we analyzed association between blood immune parameters and the functional immune reactivity of tumor-infiltrating cells after ex vivo exposure to ICB. Based on this assay, we retrospectively observed, in eight cohorts enrolling 190 MMel patients treated with ipilimumab, that PD-L1 expression on peripheral T cells was prognostic on overall and progression-free survival. Moreover, detectable CD137 on circulating CD8+ T cells was associated with the disease-free status of resected stage III MMel patients after adjuvant ipilimumab + nivolumab (but not nivolumab alone). These biomarkers should be validated in prospective trials in MMel.",

author = "N. Jacquelot and Roberti, {M. P.} and Enot, {D. P.} and S. Rusakiewicz and N. Tern{\`e}s and S. Jegou and Woods, {D. M.} and Sodr{\'e}, {A. L.} and M. Hansen and Y. Meirow and M. Sade-Feldman and A. Burra and Kwek, {S. S.} and C. Flament and M. Messaoudene and Duong, {C. P.M.} and L. Chen and Kwon, {B. S.} and Anderson, {A. C.} and Kuchroo, {V. K.} and B. Weide and F. Aubin and C. Borg and S. Dalle and O. Beatrix and M. Ayyoub and B. Balme and G. Tomasic and {Di Giacomo}, {A. M.} and M. Maio and D. Schadendorf and I. Melero and B. Dr{\'e}no and A. Khammari and R. Dummer and M. Levesque and Y. Koguchi and L. Fong and M. Lotem and M. Baniyash and H. Schmidt and Svane, {I. M.} and G. Kroemer and A. Marabelle and S. Michiels and A. Cavalcanti and Smyth, {M. J.} and Weber, {J. S.} and Eggermont, {A. M.} and L. Zitvogel",

note = "Publisher Copyright: {\textcopyright} 2017 The Author(s).",

year = "2017",

month = dec,

day = "1",

doi = "10.1038/s41467-017-00608-2",

language = "אנגלית",

volume = "8",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

Jacquelot, N, Roberti, MP, Enot, DP, Rusakiewicz, S, Ternès, N, Jegou, S, Woods, DM, Sodré, AL, Hansen, M, Meirow, Y, Sade-Feldman, M, Burra, A, Kwek, SS, Flament, C, Messaoudene, M, Duong, CPM, Chen, L, Kwon, BS, Anderson, AC, Kuchroo, VK, Weide, B, Aubin, F, Borg, C, Dalle, S, Beatrix, O, Ayyoub, M, Balme, B, Tomasic, G, Di Giacomo, AM, Maio, M, Schadendorf, D, Melero, I, Dréno, B, Khammari, A, Dummer, R, Levesque, M, Koguchi, Y, Fong, L, Lotem, M, Baniyash, M, Schmidt, H, Svane, IM, Kroemer, G, Marabelle, A, Michiels, S, Cavalcanti, A, Smyth, MJ, Weber, JS, Eggermont, AM & Zitvogel, L 2017, 'Predictors of responses to immune checkpoint blockade in advanced melanoma', Nature Communications, vol. 8, no. 1, 592. https://doi.org/10.1038/s41467-017-00608-2

TY - JOUR

T1 - Predictors of responses to immune checkpoint blockade in advanced melanoma

AU - Jacquelot, N.

AU - Roberti, M. P.

AU - Enot, D. P.

AU - Rusakiewicz, S.

AU - Ternès, N.

AU - Jegou, S.

AU - Woods, D. M.

AU - Sodré, A. L.

AU - Hansen, M.

AU - Meirow, Y.

AU - Sade-Feldman, M.

AU - Burra, A.

AU - Kwek, S. S.

AU - Flament, C.

AU - Messaoudene, M.

AU - Duong, C. P.M.

AU - Chen, L.

AU - Kwon, B. S.

AU - Anderson, A. C.

AU - Kuchroo, V. K.

AU - Weide, B.

AU - Aubin, F.

AU - Borg, C.

AU - Dalle, S.

AU - Beatrix, O.

AU - Ayyoub, M.

AU - Balme, B.

AU - Tomasic, G.

AU - Di Giacomo, A. M.

AU - Maio, M.

AU - Schadendorf, D.

AU - Melero, I.

AU - Dréno, B.

AU - Khammari, A.

AU - Dummer, R.

AU - Levesque, M.

AU - Koguchi, Y.

AU - Fong, L.

AU - Lotem, M.

AU - Baniyash, M.

AU - Schmidt, H.

AU - Svane, I. M.

AU - Kroemer, G.

AU - Marabelle, A.

AU - Michiels, S.

AU - Cavalcanti, A.

AU - Smyth, M. J.

AU - Weber, J. S.

AU - Eggermont, A. M.

AU - Zitvogel, L.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given the frequency of immune related adverse events and increasing use of ICB, predictors of response to CTLA-4 and/or PD-1 blockade represent unmet clinical needs. Using a systems biology-based approach to an assessment of 779 paired blood and tumor markers in 37 stage III MMel patients, we analyzed association between blood immune parameters and the functional immune reactivity of tumor-infiltrating cells after ex vivo exposure to ICB. Based on this assay, we retrospectively observed, in eight cohorts enrolling 190 MMel patients treated with ipilimumab, that PD-L1 expression on peripheral T cells was prognostic on overall and progression-free survival. Moreover, detectable CD137 on circulating CD8+ T cells was associated with the disease-free status of resected stage III MMel patients after adjuvant ipilimumab + nivolumab (but not nivolumab alone). These biomarkers should be validated in prospective trials in MMel.

AB - Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given the frequency of immune related adverse events and increasing use of ICB, predictors of response to CTLA-4 and/or PD-1 blockade represent unmet clinical needs. Using a systems biology-based approach to an assessment of 779 paired blood and tumor markers in 37 stage III MMel patients, we analyzed association between blood immune parameters and the functional immune reactivity of tumor-infiltrating cells after ex vivo exposure to ICB. Based on this assay, we retrospectively observed, in eight cohorts enrolling 190 MMel patients treated with ipilimumab, that PD-L1 expression on peripheral T cells was prognostic on overall and progression-free survival. Moreover, detectable CD137 on circulating CD8+ T cells was associated with the disease-free status of resected stage III MMel patients after adjuvant ipilimumab + nivolumab (but not nivolumab alone). These biomarkers should be validated in prospective trials in MMel.

UR - http://www.scopus.com/inward/record.url?scp=85029870193&partnerID=8YFLogxK

U2 - 10.1038/s41467-017-00608-2

DO - 10.1038/s41467-017-00608-2

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:85029870193

SN - 2041-1723

VL - 8

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 592

ER -

Predictors of responses to immune checkpoint blockade in advanced melanoma

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this